Growth retardation and tumour inhibition by BRCA1

Nature Genetics
J T HoltR A Jensen

Abstract

Inherited mutations in BRCA1 predispose to breast and ovarian cancer, but the role of BRCA1 in sporadic breast and ovarian cancer has previously been elusive. Here, we show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro of all breast and ovarian cancer cell lines tested, but not colon or lung cancer cells or fibroblasts. Mutant BRCA1 has no effect on growth of breast cancer cells; ovarian cancer cell growth is not affected by BRCA1 mutations in the 5' portion of the gene, but is inhibited by 3' BRCA1 mutations. Development of MCF-7 tumours in nude mice is inhibited when MCF-7 cells are transfected with wild-type, but not mutant, BRCA1. Most importantly, among mice with established MCF-7 tumours, peritoneal treatment with a retroviral vector expressing wild-type BRCA1 significantly inhibits tumour growth and increased survival.

References

Jan 1, 1995·Nature Medicine·P Libby
Apr 1, 1995·Nature Genetics·L HoskingA Jeffreys
Apr 1, 1995·Nature Genetics·S D MerajverT S Frank
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·R A JensenJ T Holt
Oct 7, 1994·Science·P A FutrealY Miki
Mar 1, 1996·Nature Genetics·R A JensenJ T Holt

❮ Previous
Next ❯

Citations

Jul 29, 1998·International Journal of Cancer. Journal International Du Cancer·S FanE M Rosen
Aug 12, 1998·International Journal of Cancer. Journal International Du Cancer·J TaylorS Ali
Nov 20, 1997·Journal of Cellular Physiology·N AuerspergH G Dyck
Feb 19, 2000·Genes, Chromosomes & Cancer·M van der LooijP Devilee
Nov 4, 2000·International Journal of Cancer. Journal International Du Cancer·R BachelierA Vincent
Jan 1, 1997·Journal of Cancer Research and Clinical Oncology·K GradeS Scherneck
May 27, 2008·Breast Cancer Research and Treatment·Thomas V O HansenFinn C Nielsen
Jul 9, 2009·Breast Cancer Research and Treatment·Sivasundaram KarnanHiroyuki Konishi
Dec 21, 2000·Current Oncology Reports·A J Li, B Y Karlan
Nov 13, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A KoivistoinenJ A Salo
Mar 8, 2002·Cellular Signalling·Karleen M Nicholson, Neil G Anderson
Jun 1, 1997·Breast Cancer Research and Treatment·J M RuppertT V Strong
Jun 16, 1999·Breast Cancer Research and Treatment·X Yang, M E Lippman
Jun 5, 2003·Breast Cancer Research and Treatment·Monique ChambonFrançoise Vignon
Jun 1, 1997·Nature Biotechnology·R S Schehr
Sep 28, 2004·Nature Cell Biology·Wael M ElShamy, David M Livingston
Mar 1, 1996·Nature Genetics·P S Steeg
Mar 1, 1996·Nature Genetics·R A JensenJ T Holt
Jun 1, 1996·Nature Genetics·Y MikiY Nakamura
Jun 1, 1997·Nature Genetics·E CoeneC R De Potter
Jul 1, 1996·Nature Genetics·C A WilsonD I Slamon
Jul 1, 1996·Nature Genetics·E V KooninP Bork
Jul 1, 1996·Nature Genetics·E P Diamandis
Nov 14, 1997·Nature Genetics
Jan 18, 2006·Cancer Gene Therapy·M A Stoff-KhaliliD T Curiel
Nov 7, 1996·The New England Journal of Medicine·O I Olopade
May 15, 1997·The New England Journal of Medicine·F J CouchB L Weber
Sep 7, 2000·DNA and Cell Biology·T OzakiA Nakagawara
Feb 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MangiaF Darvishian
May 3, 2005·The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences·Martha K McClintockFunmi Olopade
Aug 14, 2003·Human Molecular Genetics·Peter Hohenstein, Riccardo Fodde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.